A phase I study in eight patients with local recurrence of prostate cancer after hormonal therapy used adenoviral delivery of HSV-TK followed by GCV administration, resulting in a significant reduction of prostate-specific antigen (PSA, a marker of disease progression) [101]. The gene discussed is TKT; the disease is Familial prostate cancer.